
    
      Investigation on safety, tolerability and efficacy of H-1 parvovirus (H-1PV) in subjects
      suffering from glioblastoma multiforme.

      H-1PV will primarily be administered either intratumoral or intravenously. Ten days
      thereafter a complete or a subtotal tumor resection with a subsequent administration of H-1PV
      into the walls of the resection cavity will be carried out.
    
  